Rx-to-OTC switch and post-marketing safety are two key stages in the life cycle of non-prescription medicines where real-world evidence (RWE) has the potential to benefit regulatory decision making, according to a review article from the Association of the European Self-Care Industry, AESGP.
Published in the Clinical and Translational Science journal, the article “How can real-world evidence aid decision making during the life cycle of non-prescription medicines
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?